New York State Common Retirement Fund Has $17.66 Million Stake in Illumina, Inc. (NASDAQ:ILMN)

New York State Common Retirement Fund trimmed its position in Illumina, Inc. (NASDAQ:ILMN) by 24.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 126,859 shares of the life sciences company’s stock after selling 41,251 shares during the quarter. New York State Common Retirement Fund’s holdings in Illumina were worth $17,664,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. abrdn plc raised its stake in shares of Illumina by 764.9% in the fourth quarter. abrdn plc now owns 339,023 shares of the life sciences company’s stock valued at $47,206,000 after purchasing an additional 299,827 shares in the last quarter. J.P. Morgan Private Wealth Advisors LLC acquired a new position in shares of Illumina in the third quarter valued at $29,558,000. International Assets Investment Management LLC raised its stake in shares of Illumina by 210.5% in the fourth quarter. International Assets Investment Management LLC now owns 48,194 shares of the life sciences company’s stock valued at $6,711,000 after purchasing an additional 32,672 shares in the last quarter. Aquila Investment Management LLC raised its stake in shares of Illumina by 150.0% in the fourth quarter. Aquila Investment Management LLC now owns 25,000 shares of the life sciences company’s stock valued at $3,481,000 after purchasing an additional 15,000 shares in the last quarter. Finally, Weil Company Inc. raised its stake in Illumina by 59.2% during the third quarter. Weil Company Inc. now owns 22,963 shares of the life sciences company’s stock worth $3,152,000 after acquiring an additional 8,539 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have issued reports on ILMN shares. HSBC lowered Illumina from a “buy” rating to a “hold” rating in a research note on Tuesday, January 16th. StockNews.com upgraded Illumina from a “hold” rating to a “buy” rating in a research note on Friday, February 16th. Stephens reiterated an “overweight” rating and set a $170.00 price objective on shares of Illumina in a research note on Wednesday, April 10th. Barclays increased their price objective on Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a research note on Wednesday, April 10th. Finally, OTR Global restated a “mixed” rating on shares of Illumina in a report on Wednesday, March 20th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, Illumina currently has an average rating of “Hold” and an average price target of $167.70.

Illumina Price Performance

Shares of ILMN opened at $122.28 on Monday. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.26. Illumina, Inc. has a 1 year low of $89.00 and a 1 year high of $213.91. The stock has a market cap of $19.47 billion, a P/E ratio of -16.66 and a beta of 1.19. The stock’s 50-day moving average price is $131.51 and its two-hundred day moving average price is $127.24.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. The firm had revenue of $1.12 billion for the quarter, compared to analysts’ expectations of $1.09 billion. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The company’s revenue was up 3.6% compared to the same quarter last year. During the same quarter last year, the business earned $0.14 earnings per share. On average, equities analysts predict that Illumina, Inc. will post 0.91 earnings per share for the current year.

Insider Transactions at Illumina

In other Illumina news, CEO Jacob Thaysen purchased 7,330 shares of the company’s stock in a transaction dated Thursday, February 22nd. The shares were bought at an average price of $135.29 per share, with a total value of $991,675.70. Following the completion of the transaction, the chief executive officer now directly owns 14,861 shares in the company, valued at approximately $2,010,544.69. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.17% of the stock is currently owned by insiders.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.